Advertisement

Drug Safety

, Volume 39, Issue 3, pp 209–218 | Cite as

Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review

  • Rose I. Okonkwo
  • Anita E. Weidmann
  • Emmanuel E. Effa
Systematic Review

Abstract

Introduction

Tenofovir disoproxil fumarate (TDF)-containing regimens in the treatment of HIV-infected children have safety concerns with respect to renal and bone toxicity.

Objective

The aim of this study was to systematically review and critically appraise the literature relating to the reported renal and bone adverse effects of TDF-based regimens in the treatment of HIV-infected children from 2 to 19 years old.

Methods

Searches were performed using the Cochrane Central Register of Controlled Trials (CENTRAL), Cumulative Index to Nursing and Allied Health Literature (CINAHL), MEDLINE, OvidSP, ScienceDirect and Web of Science databases and platforms. All primary studies involving tenofovir use in HIV-infected children were sought. Studies that involved the use of TDF for pre- and post-exposure prophylaxis, and treatment of chronic hepatitis B virus infection were excluded. Data on study characteristics, participant’s characteristics, therapeutic intervention and adverse effects were extracted using a piloted tool. In addition, pharmacovigilance data from the WHO Adverse Reaction database were included.

Results

We identified 19 studies that reported the presence of renal and bone adverse effects of TDF and these included a total of 1100 study participants. The reports were in distinctly heterogeneous participant groups. A total of 287 renal and bone adverse effects were reported (250 renal and 37 bone adverse effects). Approximately 238 (21.6 %) participants were affected by these adverse effects. Of these, 15 participants stopped their TDF-containing regimen due to these adverse effects. In addition, the pharmacovigilance data from the WHO Adverse Reaction database reported 101 renal and bone adverse effects for patients whose indication was HIV/AIDS.

Conclusion

This systematic review summarises the reports of renal and bone adverse effects of a TDF-containing regimen in the treatment of HIV-infected children. Our findings suggest that the benefits of using TDF in children need to be balanced against the potential risk of toxicity.

Keywords

Bone Mineral Density Tenofovir Electronic Supplementary Material Table Tenofovir Disoproxil Fumarate Fanconi Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The authors would like to thank Mr. Ekpereonne Esu for his timely help in literature search strategies and study selection process and Dr. Christopher Akolo for retrieval of some full-text studies.

Compliance with Ethical Standards

Funding

No sources of funding were used to assist in the preparation of this study.

Conflicts of interest

Rose Okonkwo, Anita Weidmann and Emmanuel Effa have no conflicts of interest that are directly relevant to the content of this study.

Supplementary material

40264_2015_371_MOESM1_ESM.pdf (216 kb)
Supplementary material 1 (PDF 216 kb)

References

  1. 1.
    Joint United Nations Programme on HIV/AIDS. 2014 gap report. Geneva: UNAIDS; 2014. http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS_Gap_report_en.pdf. Accessed 10 Mar 2015.
  2. 2.
    Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR 3rd, et al. Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345(21):1522–8.CrossRefPubMedGoogle Scholar
  3. 3.
    AIDSinfo. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Rockville: AIDSinfo; 2014. http://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv-guidelines/0. Accessed 12 Mar 2014.
  4. 4.
    Pozniak A. Tenofovir: what have over 1 million years of patient experience taught us? Int J Clin Pract. 2008;62(8):1285–93.CrossRefPubMedGoogle Scholar
  5. 5.
    Gilead Sciences, Inc. US Food and Drug Administration approves new formulations of Viread® for use by children living with HIV. Foster City: GSI; 2012. http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1650180&highlight=. Accessed 23 Jan 2014.
  6. 6.
    World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: WHO; 2013. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1. Accessed 10 Jan 2014.
  7. 7.
    US Food and Drug Administration. Drugs@FDA. Viread. Maryland: US FDA; 2012. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed 19 Jan 2014.
  8. 8.
    Kearney BP, Abadi J, Rosenberg M, Nguyen M, Yale K, Flaherty J, et al. Pharmacokinetics (PK) of tenofovir DF (TDF) oral suspension in HIV-1 infected children between 2 and 8 years of age [poster]. 11th Conference on Retroviruses and Opportunistic Infections: 8–11 Feb 2004; San Francisco.Google Scholar
  9. 9.
    Hazra R, Gafni RI, Maldarelli F, Balis FM, Tullio AN, DeCarlo E, et al. Tenofovir disoproxil fumarate and an optimized background regime of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics. 2005;116(6):e846–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Riordan A, Judd A, Boyd K, Cliff D, Doerholt K, Lyall H, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland. Pediatr Infect Dis J. 2009;28(3):204–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Vigano A, Zuccotti GV, Martelli L, Giacomet V, Cafarelli L, Borgonovo S, et al. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin Drug Investig. 2007;27(8):573–81.CrossRefPubMedGoogle Scholar
  12. 12.
    Hussain S, Khayat A, Tolaymat A, Rathore MH. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr Nephrol. 2006;21(7):1034–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Hawkins S, Ball C. Adverse events experienced by three children taking tenofovir and didanosine in combination. HIV Med. 2007;8(6):411.CrossRefPubMedGoogle Scholar
  14. 14.
    Gafni RJ, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006;118(3):e711–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr. 2008;152(4):582–4.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. [updated March 2011]. The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org. Accessed 21 Jan 2014.
  17. 17.
    Centre for Reviews and Dissemination. Systematic reviews: CRD’s guidance for undertaking reviews in health care. York: CRD; 2009. http://www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf. Accessed 21 Jan 2014.
  18. 18.
    Loke YK, Price D, Herxheimer A. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol. 2007;7:32.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Golder S, McIntosh HM, Duffy S, Glanville J, Centre for Reviews and Dissemination and UK Cochrane Centre Search Filters Design Group. Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE. Health Info Libr J. 2006;23:3–12.CrossRefPubMedGoogle Scholar
  20. 20.
    The Uppsala Monitoring Centre. Pharmacovigilance: WHO Programme Members. Uppsala: UMC; 2014. http://www.who-umc.org/DynPage.aspx?id=100653&mn1=7347&mn2=7252&mn3=7322&mn4=7442. Accessed 20 Jun 2014.
  21. 21.
    Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute; 2014. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 30 May 2014.
  22. 22.
    Sackett DL, Wennberg JE. Choosing the best research design for each question. BMJ. 1997;315:1636.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Negra MD, Carvalho AP, Aquino MZ, Silva MT, Pinto J, White K, et al. A randomized study of tenofovir disoproxil fumarate in treatment- experienced HIV-1 infected adolescents. Pediatr Infect Dis J. 2012;31(5):469–73.CrossRefPubMedGoogle Scholar
  24. 24.
    Saez-Llorens X, Castaño E, Rathore M, Church J, Deville J, Gaur A, et al. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in human immunodeficiency virus-1 infected children with virologic suppression. Pediatr Infect Dis J. 2015;34(4):376–82. doi: 10.1097/INF.0000000000000289.CrossRefPubMedGoogle Scholar
  25. 25.
    Lim Y, Lim W, Lyall H, Foster C. Tenofovir-associated nephrotoxicity in children with perinatally acquired HIV infection: a single centre cohort. In: The Family Clinic, Department of Pediatrics. Imperial College Healthcare NHS Trust. (Oral Presentation)Google Scholar
  26. 26.
    Papaleo A, Warszawski J, Salomon R, Jullien V, Veber F, Dechaux M, et al. Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir. Pediatr Infect Dis J. 2007;26(10):949–51.CrossRefPubMedGoogle Scholar
  27. 27.
    Pontrelli G, Cotugno N, Amodio D, Zangari P, Tchidjou HK, Baldassari S, et al. Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors. BMC Infect Dis. 2012;12:18.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Purswani M, Patel K, Kopp JB, Seage GR 3rd, Chernoff MC, Hazra R, et al. Tenofovir treatment duration predicts proteinuria in a multiethnic United States cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J. 2013;32(5):495–500.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Soler-Palacín P, Melendo S, Noguera-Julian A, Fortuny C, Navarro ML, Mellado MJ, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS. 2011;25(2):171–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Costa M, Teixeira C, Costa AM, Faria MS, Mota C, Marques L. Nephrogenic diabetes insipidus associated with tenofovir administration: report of a paediatric case. Port J Nephrol Hypert. 2012;26(2):171–3.Google Scholar
  31. 31.
    Gracey DM, Fernando M, Ziegler J, White CP, Post JJ. An unrecognised case of tenofovir-associated Fanconi syndrome. Med J Aust. 2012;196:111–2.CrossRefPubMedGoogle Scholar
  32. 32.
    Lucey JM, Hsu P, Ziegler JB. Tenofovir-related Fanconi’s syndrome and osteomalacia in a teenager with HIV. BMJ Case Rep. 2013;2013:1–4. doi: 10.1136/bcr-2013-008674.Google Scholar
  33. 33.
    Bengleil AS, Kambraki M, Al Fituri O, El Ammari I, Idris EA, Martino AM. Tenofovir toxicity in children: two clinical cases [abstract no. P214]. 9th International Congress on Drug Therapy in HIV Infection; 9–13 Nov 2008; Glasgow. http://www.hiv9.com. Accessed 23 May 2014.
  34. 34.
    Giacomet V, Cattaneo D, Viganò A, Nannini P, Manfredini V, Ramponi G, et al. Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes. Pediatr Infect Dis J. 2013;32(10):e403–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Wood SM, Shah SS, Steenhoff AP, Meyers KEC, Kaplan BS, Rutstein RM. Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males. AIDS Patient Care STDs. 2009;23(1):1–4.CrossRefPubMedGoogle Scholar
  36. 36.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W–65.Google Scholar
  37. 37.
    Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dise. 2010;51(5):496–505.CrossRefGoogle Scholar
  38. 38.
    Viganò A, Bedogni G, Manfredini V, Giacomet V, Cerini C, di Nello F, et al. Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study. Clin Drug Investig. 2011;31(6):407–15.CrossRefPubMedGoogle Scholar
  39. 39.
    Aurpibul L, Thanyawee P. Review of tenofovir use in HIV-infected children. Pediatr Infect Dis J. 2015;34(4):383–91.CrossRefPubMedGoogle Scholar
  40. 40.
    Hall AM. Update on tenofovir toxicity in the kidney. Pediatr Nephrol. 2013;28:1011–3.CrossRefPubMedGoogle Scholar
  41. 41.
    Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Nino MD, Izquierdo MC, Poveda J, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:354908.PubMedCentralPubMedGoogle Scholar
  42. 42.
    Thomas V, Purdy J, Reynolds J, Hadigan C, Hazra R. Bone mineral density in adolescents infected with HIV perinatally or childhood: data from the NIH intramural program [abstract]. 16th Conference on Retroviruses and Opportunistic Infections (CROI); 8–11 Feb 2009; Montreal.Google Scholar
  43. 43.
    Jacobson D, Dimeglio L, Hazra R, et al. Clinical determinants of bone mineral density in perinatally HIV-infected children [abstract]. 16th Conference on Retroviruses and Opportunistic Infections (CROI); 8–11 Feb 2009; Montreal.Google Scholar
  44. 44.
    Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26(7):825–31.CrossRefPubMedGoogle Scholar
  45. 45.
    Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Viganò A. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J Acquir Immune Defic Syndr. 2005;40(4):448–50.CrossRefPubMedGoogle Scholar
  46. 46.
    Viganò A, Zuccotti GV, Puzzovio M, Pivetti V, Zamproni I, Cerini C, et al. Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths. Antivir Ther. 2010;15(7):1053–8.CrossRefPubMedGoogle Scholar
  47. 47.
    Vigano A, Aldrovandi GM, Giacomet V, Merlo M, Martelli L, Beretta S, et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antivir Ther. 2005;10(8):917–24.PubMedGoogle Scholar
  48. 48.
    Bunders MJ, Frinking O, Scherpbier HJ, van Arnhem LA, van Eck-Smit BL, Kuijpers TW, et al. Bone mineral density increases in HIV-infected children treated with long-term combination antiretroviral therapy. Clin Infect Dis. 2013;56(4):583–6.CrossRefPubMedGoogle Scholar
  49. 49.
    Fabiano V, Giacomet V, Viganò A, Bedogni G, Stucchi S, Cococcioni L, et al. Long-term body composition and metabolic changes in HIV-infected children switched from stavudine to tenofovir and from protease inhibitors to efavirenz. Eur J Pediatr. 2013;172(8):1089–96.CrossRefPubMedGoogle Scholar
  50. 50.
    Rosso R, Parodi A, Torrisi C, De Terlizzi F, Viscoli C, Vignolo M. A tailored dose of tenofovir could reduce its impact on bone mass in HIV Type 1-infected children and adolescents: a report from 5 years of clinical experience. AIDS Res Hum Retroviruses. 2010;26(12):1265–6.CrossRefPubMedGoogle Scholar
  51. 51.
    Zamboni G, Antoniazzi F, Bertoldo F, Lauriola S, Antozzi L, Tato L. Altered bone metabolism in children infected with human immunodeficiency virus. Acta Paediatr. 2003;92:12–6.CrossRefPubMedGoogle Scholar
  52. 52.
    Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Vigano A. Bone mineral loss through increased bone turnover in HIV infected children treated with highly active antiretroviral therapy. AIDS. 2001;15:1823–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Vigano A. Longitudinal changes of bone mineral density and metabolism in antiretroviral treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab. 2004;89:24–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Stagi S, Bindi G, Galluzzi F, Galli L, Salti R, de Martino M. Changed bone status in human immunodeficiency virus type 1 (HIV-1) perinatally infected children is related to low serum free IGF-I. Clin Endocrinol. 2004;61(692):699.Google Scholar
  55. 55.
    Schtscherbyna A, Pinheiro MF, de Mendonça LM, Gouveia C, Luiz RR, Machado ES, et al. Factors associated with low bone mineral density in a Brazilian cohort of vertically HIV-infected adolescents. Int J Infect Dis. 2012;16:e872–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Rose I. Okonkwo
    • 1
  • Anita E. Weidmann
    • 2
  • Emmanuel E. Effa
    • 3
  1. 1.Department of Child HealthUniversity of Benin Teaching HospitalBenin CityNigeria
  2. 2.School of Pharmacy, Faculty of Health and Social CareRobert Gordon UniversityAberdeenUK
  3. 3.Internal Medicine, Faculty of Medicine and DentistryUniversity of CalabarCalabarNigeria

Personalised recommendations